Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Orf5.5
Orforglipron – Forschung
Überwiegend Mechanismus / Beobachtung
39 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Orforglipron sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2023–2026 mit einer typischen Studiengröße von 559 Teilnehmenden.
Basierend auf 39 Studien · 10 Meta-Analysen · 17 RCTs · 15,603 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Blood sugar & glycemic controlGroße HbA1c-Senkungen bei Typ-2-Diabetes über Phase 2 (bis zu ~2.1%) und Phase 3 (ACHIEVE-1); überlegen gegenüber dapagliflozin und additiv zu insulin glargine · Wochen bis Monate
Überwiegend Mechanismus / Beobachtung28 Studien
Weight managementEtwa 9-15% Gewichtsverlust bei Adipositas in Phase 2 nach 36 Wochen; ATTAIN-1 (Phase 3) zeigte ~11.2% mittleren Verlust nach 72 Wochen bei 36 mg gegenüber ~2.1% Placebo · Monate (titriert)
Überwiegend Mechanismus / Beobachtung20 Studien
Safety & adverse effects
Überwiegend Mechanismus / Beobachtung7 Studien
Aktives Forschungsgebiet
39 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
20232026
1RCTn=3,127 · very large study2025
Einfach gesagt: The mean change in body weight from baseline to week 72 was -7.5%... with 6 mg of orforglipron, -8.4%... with 12 mg, and -11.2%... with 36 mg, as compared with -2.1%... with placebo (P<0.001 for all comparisons).
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. · N Engl J Med (2025)
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Mean weight loss -11.2% at 36 mg vs -2.1% placebo; ≥10% loss in 54.6%, ≥15% in 36.0%, ≥20% in 18.4% (36 mg)
Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved vs placebo
Einfach gesagt: At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 with the 12-mg dose, -1.48 with the 36-mg dose, and -0.41 with placebo.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. · N Engl J Med (2025)
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
All doses superior to placebo on HbA1c (placebo-adjusted up to -1.07 percentage points); mean HbA1c reached ~6.5-6.7%
Einfach gesagt: While gastrointestinal tolerability remains a clinically important limitation requiring mitigation strategies, orforglipron represents a promising oral therapeutic option for comprehensive obesity and metabolic management.
Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, Iftikhar S, Saddique MN, Alfalh W, Omar RMB, Abu Dawood H. · Endocrinology, diabetes & metabolism (2025)
Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models.
Orforglipron demonstrated dose-dependent reductions in body weight from 2.48% at 3 mg to 9.8% at 45 mg, BMI from 0.89 to 3.62 kg/m 2 , waist circumference from 1.57 to 6.9 cm, and HbA1c from 0.76% to 1.04% compared with placebo.
Favourable lipid changes included reductions in total cholesterol (MD: -4.51% [95% CI: -6.91 to -2.11]), LDL-C (MD: -5.34% [95% CI: -7.10 to -3.58]), and triglycerides (MD: -10.07% [95% CI: -12.33 to -7.80]), with increased HDL-C (MD: 2.94% [95% CI: 1.38 to 4.49]).
Einfach gesagt: Change from baseline in mean HbA1c was -1.23%, -1.50%, and -1.56% with orforglipron 3 mg, 12 mg, and 36 mg, respectively, versus -0.81% with dapagliflozin 10 mg.
Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. · Lancet (2026)
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
All orforglipron doses non-inferior and statistically superior to dapagliflozin on HbA1c (treatment differences -0.42% to -0.75%; all p<0.0001)
Mild-to-moderate GI events in 46-54% of orforglipron groups vs 12% with dapagliflozin
Einfach gesagt: TSA indicates conclusions for weight, BMI, and SBP are robust; longer-term comparative trials should refine DBP and safety signals.
Jamal A, Khan S, Qadri M, Shah A, Iftikhar H, Fatima E, Ahmad M, Sikandar M, Jawed I, Muneeb M, Mohmand MS, Bacha Z, Khan BW, Jamal T, Khalid AA, Khan MI, Zulkaif M. · Acta diabetologica (2026)
METHODS: Following PRISMA 2020, randomized controlled trials comparing orforglipron with placebo were combined using random-effects meta-analysis to determine mean differences (MD) or risk ratios (RR) with 95% confidence intervals.
Fasting plasma glucose decreased significantly overall (MD − 25.77 mg/dL, 95% CI − 58.70 to − 7.18; very high heterogeneity; dose-response evident).
Diastolic blood pressure was neutral (primary MD − 0.32 mmHg, 95% CI − 2.36 to 1.71; sensitivity MD + 0.68 mmHg, 95% CI − 0.02 to 1.39).
Einfach gesagt: At week 40, the mean changes from baseline in HbA1c were -1.58%, -1.88%, and -1.82% with orforglipron 3 mg, 12 mg, and 36 mg once daily, respectively, vs -0.79% with placebo.
Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. · JAMA (2026)
Phase-3 double-blind RCT (n=546) of orforglipron 3/12/36 mg vs placebo added to titrated insulin glargine in type 2 diabetes over 40 weeks
Each dose superior to placebo on HbA1c (placebo-adjusted -0.78% to -1.08%; P<.001)
Mean body-weight change -2.6% to -5.4% vs +0.2% placebo